Table 1.
Characteristics of patients with MBC who received abemaciclib after disease progression on a prior CDK4/6i (N=52)
| Parameter | n (%)* |
|---|---|
| Mean age (range), y | |
| Original diagnosis | 47.5 (29–75) |
| Diagnosis of metastasis | 53 (35–75) |
| Sex | |
| Female | 50 (96) |
| Male | 2 (4) |
| Race/ethnicity | |
| White | 38 (73) |
| Black | 4 (8) |
| Hispanic | 2 (4) |
| Asian/Pacific Islander | 5 (10) |
| Other | 3 (6) |
| Abemaciclib sequence following prior CDK4/6i | |
| Sequential | 18 (35) |
| Non-sequential | 34 (65) |
| Abemaciclib treatment course | |
| Monotherapy | 15 (29) |
| Endocrine partner | 37 (71) |
| Aromatase inhibitor | 3 (6) |
| Fulvestrant | 34 (65) |
| Clinical outcome on abemaciclib at data cutoff (July 1, 2022) | |
| On treatment | 13 (25) |
| Discontinued, progressive disease | 39 (75) |
| Prior CDK4/6i treatment course | |
| Ribociclib | 1 (2) |
| Palbociclib | 51 (98) |
| Endocrine partner | |
| Aromatase inhibitor | 34 (65) |
| SERD | |
| Fulvestrant | 17 (33) |
| other | 1 (2) |
| Mean duration of CDK4/6i treatment, months (range) | |
| First CDK4/6i (palbociclib or ribociclib) | 11.1 (1 – 43.6) |
| Second CDK4/6i (abemaciclib) | 7.6 (0.9 – 29.3) |
| Other treatment lines prior to abemaciclib, metastatic setting (nonsequential cohort) | |
| Chemotherapy | 26 (50) |
| Everolimus | 11 (21) |
| Tamoxifen | 7 (14) |
| Alpelisib | 2 (4) |
| Bevacizumab | 1 (2) |
| Olaparib | 1 (2) |
| Megestrol | 1 (2) |
*
Data are presented as n(%) unless otherwise specified